sialic acid binding Ig like lectin 11Genealiases: []
Q-omics provides the consensus-scored SIGLEC11 profile across patient tissues and cancer cell-line models. SIGLEC11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SIGLEC11 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SIGLEC11 RNA expression shows 15,073 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where SIGLEC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC11 survival associations across molecular data types. SIGLEC11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC11 RNA expression–survival associations across cancer types. High SIGLEC11 expression shows unfavorable associations in KIRC, ACC and THCA, but favorable associations in HNSC, SKCM and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SIGLEC11 RNA expression.
This table summarizes SIGLEC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLEC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC11 shows lower tumor expression in COAD, THCA, LUAD, KICH, LUSC and LIHC. The COAD box plot shows higher SIGLEC11 RNA expression in normal versus tumor tissue (log2 FC = −0.591, t-test p < 0.001).
This table shows molecular features associated with SIGLEC11 in patient tissues and cancer cell lines. In patient samples, SIGLEC11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGLEC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
